Home › Triple-Negative Breast Cancer › Virginia › Charlottesville
Triple-Negative Breast Cancer clinical trials in Charlottesville, VA
4 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Charlottesville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- University of Virginia, Charlottesville
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- University of Virginia, Charlottesville
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
RecruitingPhase 2
- University of Virginia Comprehensive Cancer Center, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Virginia, Charlottesville
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Charlottesville
- Non-Small Cell Lung Cancer21 studies
- Acute Myeloid Leukemia16 studies
- Prostate Cancer15 studies
- Cancer (all types)13 studies
- Endometrial Cancer13 studies
- Metastatic Cancer13 studies
- Lung Cancer13 studies
- Heart Failure12 studies
- Colorectal Cancer10 studies
- Ovarian Cancer10 studies
- Type 1 Diabetes9 studies
- Breast Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.